Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies from University of Regensburg have provided new data on breast cancer
May 29th, 2008
" The HER ( human EGFR related) family of receptor tyrosine kinases ( HER1/EGFR ( epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/ c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intracellular signal transduction pathways resulting in receptor interaction and cross-activation," researchers in Regensburg, Germany report. "The most famous family member is HER2, which is a target in Herceptin T therapy in metastatic status and also in adjuvant therapy of breast cancer in the event of dysregulation as a result of gene amplification and resulting...
Source: Women's Health Weekly (2008-05-29)
|
